30 April 2026
30 April 2026
The PRIME status for RTx-015 was granted based on preliminary Phase I/II safety and efficacy clinical data.
The TAVVE study will begin later this year with ten patients, whose 30-day safety results will be submitted to the FDA.
PBGENE-DMD aims to deliver sustained muscle function improvement for DMD patients with mutations between exons 45 and 55.
Ultreon 3.0 uses AI and OCT to provide real-time, high-resolution imaging during minimally invasive heart procedures.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
